Parmax Pharma Ltd is an India-based company, which is engaged in active pharmaceutical ingredients (API) and contract manufacturing operations (CMO) business. It uses quality by design techniques to produce complex molecules enabling customers to create formulations. The Company’s manufacturing units run in accordance with current good manufacturing practices (cGMP). Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Ormeloxifene Hydrochloride I.P., Milnacipram HCl, Calciumpoly Carbophil usp, Levosulpride, Paliperidone, Edaravone, Lacosamide, Iloperidone, Prasugrel HCl, 2-Acetyl Thiophene, Morpholine Hydrochloride, Camphor Sulfonyl Chloride, ISB-I (2-Chlorobenzaldehyde-5-Sulfonic acid disodium salt), Benzaldehyde-2, 5-Di-Sulfonic acid disodium salt, 2-picolinoxylidide, 4-Octyl amino pyridine (4-OAP), Sitagliptin phosphate Monohydrate API, Solifenacin Succinate API, Vilazodone Hydrochloride API, and Azelnidipine API.
Parmax Pharma Limited Financial Highlights
- Revenue: Parmax Pharma Limited reported revenue of ₹12.16 crore in FY26 vs ₹28.24 crore in FY25. It showed a decrease of 56.94% on a yearly basis.
- Operating Profit: Parmax Pharma Limited reported an operating loss of ₹5.85 crore in FY26 vs ₹2.40 crore in FY25. It showed a decrease of 143.75% on a year-on-year basis.
- Net Profit: Parmax Pharma Limited reported a net loss of ₹4.16 crore in FY26 vs ₹2.09 crore in FY25. It showed a decrease of 99.04% on a yearly basis.
Parmax Pharma Limited Quarterly Result Highlights
- Parmax Pharma Limited reported revenue of ₹3.34 crore in Mar 2026, compared with ₹4.34 crore in Dec 2025, representing a decrease of 23.04% on a quarter-on-quarter (QoQ) basis.
- Parmax Pharma Limited reported an operating loss of ₹2.27 crore in Mar 2026, compared with ₹0.73 crore in Dec 2025, representing a decrease of 210.96% on a quarter-on-quarter (QoQ) basis.
- Parmax Pharma Limited reported a loss of ₹0.58 crore in Mar 2026, compared with ₹0.73 crore in Dec 2025, reflecting an increase of 20.55% on a QoQ basis.
- The earnings per share (EPS) of Parmax Pharma Limited stood at ₹5.60 during Mar 2026.
